KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (Weighted Average) (2016 - 2025)

NovoCure (NVCR) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $111.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.37% to $111.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.5 million through Dec 2025, up 3.37% year-over-year, with the annual reading at $111.5 million for FY2025, 3.37% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $111.5 million in Q4 2025 for NovoCure, roughly flat from $111.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $111.9 million in Q3 2025 to a low of $102.6 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $106.6 million across 5 years, with a median of $106.2 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 0.79% in 2022 and later grew 3.93% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $103.4 million in 2021, then rose by 1.19% to $104.7 million in 2022, then rose by 1.65% to $106.4 million in 2023, then rose by 1.36% to $107.8 million in 2024, then rose by 3.37% to $111.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for NVCR at $111.5 million in Q4 2025, $111.9 million in Q3 2025, and $111.6 million in Q2 2025.